Quantcast

Latest Algeta ASA Stories

2009-01-14 04:00:00

OSLO, Norway, January 14 /PRNewswire-FirstCall/ -- - Results Highlight the Potential of Alpharadin to Treat Bone Metastases in Major Cancer Indications Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that with the results of the BC1-04 study reported today it has completed its comprehensive phase II clinical program evaluating Alpharadin (radium-223) as a new treatment for bone metastases in patients with hormone-refractory prostate cancer (HRPC).

2008-12-11 07:24:00

OSLO, December 11 /PRNewswire-FirstCall/ -- - Appointment Enhances Algeta's Commercial Capabilities and Aims to Accelerate Further Development of Alpharadin in Advanced Prostate Cancer Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, announces that Mr.

2008-08-28 09:01:23

Algeta ASA, the Norwegian cancer therapeutics company, has announced that its BC1-03 Phase II pain palliation study met its primary objective.

2008-08-28 06:00:18

OSLO, August 28 /PRNewswire-FirstCall/ -- - Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC) Algeta ASA , the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met.


Word of the Day
begunk
  • To befool; deceive; balk; jilt.
  • An illusion; a trick; a cheat.
The word 'begunk' may come from a nasalised variant of Scots begeck ("to deceive, disappoint"), equivalent to be- +‎ geck.